CSGALNACT1 Polyklonale Antilichaam, APC-vervoeging

The chondroitin N-acetylgalactosaminyltransferase family includes Beta-1,4-GalNAc-T, Beta-1,4-GalNAc-T2, Beta-1,4-GalNAc-T3 and Beta-1,4-GalNAc-T4. The Beta-1,4-GalNAc-T protein consists of a short N-terminal residue, a transmembrane region and a long C-terminal residue, which includes a catalytic domain and localizes to the Golgi apparatus. Beta-1,4-GalNAc-T utilizes simple ganglioside GM3 as a substrate for more complex gangliosides GM2, GM1 and GD1a. Beta-1,4-GalNAc-T is expressed in normal brain tissues and in various malignant transformed cells, such as malignant melanoma, neuroblastoma and adult T cell leukemia. Mice lacking the Beta-1,4-GalNAc-T protein develop significant and progressive behavioral neuropathies, including deficits in reflexes, strength, coordination and balance. Beta-1,4-GalNAc-T is a potential molecular marker for detecting melanoma cells and monitoring tumor progression.

4-N-acetylgalactosaminyltransferase 1; Beta4GalNAcT 1; beta4GalNAcT; Beta4GalNAcT-1; Beta4GalNAcT1; CGAT1_HUMAN; ChGn; Chondroitin beta-1; Chondroitin beta1 4 N acetylgalactosaminyltransferase; Chondroitin beta1 4 N acetylgalactosaminyltransferase 1; Chondroitin sulfate N acetylgalactosaminyltransferase 1; Chondroitin sulfate N-acetylgalactosaminyltransferase 1; CSGalNAcT 1; CsGalNAcT-1; Csgalnact1; FLJ11264; FLJ13760.

55790

Cytoplasm, Cell membrane

101-200/532

CSGALNACT1

APC

KLH conjugated synthetic peptide derived from human CSGALNACT1

IF (IHC-P), IF (IHC-F), IF (ICC)

Purified by Protein A.

650nm/660nm

1µg/µl

IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

55790

Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse, Chicken